Aniridia–Renal Agenesis Psychomotor Retardation (ARAP) Syndrome is an extremely rare condition reported in just two siblings in 1974. The triad included eye abnormalities (partial aniridia, congenital glaucoma, telecanthus), facial features (frontal bossing, hypertelorism), unilateral renal agenesis (one kidney absent), and mild psychomotor delay. No additional cases have been robustly documented since that original report. Alternative labels you may see include “Aniridia-renal agenesis-psychomotor retardation” and “Sommer–Rathbun–Battles syndrome.” Because so few cases exist, there is no dedicated treatment trial; management is extrapolated from evidence for aniridia, solitary kidney care, and developmental interventions. Qeios+4Genetic Diseases Info Center+4Orpha+4
Many people notice that ARAP’s features overlap with WAGR (Wilms tumor–Aniridia–Genitourinary anomalies–Range of neurodevelopmental differences), a contiguous gene deletion disorder on 11p13 involving PAX6 and WT1. In WAGR, aniridia is common and kidney/urogenital anomalies result from WT1 haploinsufficiency; tumor surveillance is standard. By contrast, ARAP was a two-sibling report with unilateral renal agenesis and partial aniridia; its exact genetic basis is unknown. In any individual with aniridia plus kidney anomalies, expert sources recommend molecular testing to rule in/out 11p13 deletion because management (e.g., Wilms tumor screening) changes if WT1 is deleted. NORD+3Medscape+3NCBI+3
This is an extremely rare genetic condition that was reported in two siblings from the same family. It combines three main features:
Aniridia – the colored part of the eye (iris) is partly missing, so the eyes may look very dark and are very sensitive to light.
Renal agenesis – one kidney did not form (a “single kidney”).
Psychomotor delay – movement and overall development are slower than usual in early life.
Along with the triad above, the original description also noted congenital glaucoma, telecanthus (the inner corners of the eyes sit farther apart), frontal bossing (prominent forehead), and hypertelorism (eyes set wider apart). No additional families have been published since the original 1974 report, so medical knowledge is limited and based on very few patients. Genetic Diseases Info Center+1
Current reference summaries describe the condition as likely inherited in an autosomal-recessive way (a child would need two altered copies of the same gene). However, the exact gene is unknown. Genetic Diseases Info Center
Other names
Sommer–Rathbun–Battles syndrome (historical name used in the early report). Wikipedia
You may also see catalog entries that group it under rare “aniridia with renal anomalies” and list registry IDs (e.g., Orphanet ORPHA:1064; OMIM 206750). Wikipedia+1
Types
There are no official subtypes in the medical literature because only one family has been described. Clinicians sometimes use practical groupings to communicate with families:
Ocular-dominant pattern – eye findings (aniridia, glaucoma, corneal clouding, strabismus) are most noticeable.
Renal-dominant pattern – a single kidney is the key feature; the other findings are milder.
Neurodevelopmental-dominant pattern – developmental delay, low muscle tone, and poor balance are the most obvious problems.
These groupings are educational, not formal medical subtypes.
Causes
Only one cause is established for this named syndrome:
An unknown autosomal-recessive genetic change affecting early development of both the eyes and kidneys. The specific gene has not been identified. Genetic Diseases Info Center
Because the gene is not yet known, genetic evaluation focuses on conditions with overlapping features. The items below are mechanisms and genes doctors consider in the differential diagnosis (they have not been proven causes of this named syndrome, but they can mimic parts of the triad):
PAX6 variants – a common cause of aniridia (with or without other problems). NCBI
Contiguous 11p13 deletions of PAX6 and WT1 (WAGR spectrum) – produce aniridia plus kidney/genitourinary problems and developmental issues; these deletions are autosomal dominant, not recessive, and represent a different diagnosis. NCBI
HNF1B haploinsufficiency / 17q12 deletion – a major cause of congenital kidney anomalies (sometimes with developmental differences). NCBI
PAX2 variants – cause renal-coloboma syndrome (kidney anomalies plus eye malformations, though typically coloboma rather than aniridia). MedlinePlus
GREB1L variants – associated with unilateral or bilateral renal agenesis and other urinary/reproductive tract anomalies. BioMed Central
Other CAKUT-related gene defects (broader congenital anomalies of the kidney/urinary tract), where the eye findings are absent or different and thus would indicate a different diagnosis. MedlinePlus
Noncoding/regulatory changes near developmental genes (e.g., alterations that change gene expression without changing the coding sequence), which are recognised mechanisms in aniridia and related disorders. NCBI
Chromosomal microdeletions/duplications outside 11p13 that affect eye–kidney developmental networks (detected by microarray). NCBI
Mosaicism (a genetic change present in some cells but not others) that can modify the presentation in related conditions. NCBI
Splice-site variants in eye or kidney developmental genes (well-documented across aniridia/WAGR genetics). NCBI
Loss-of-function (nonsense/frameshift) variants in early developmental regulators (general mechanism). NCBI
Missense variants in DNA-binding domains of transcription factors important to eye/kidney morphogenesis (general mechanism). NCBI
Epigenetic dysregulation of developmental genes (general mechanism considered when sequencing is unrevealing). NCBI
Uniparental disomy or imprinting effects involving regions that regulate renal and ocular development (rare mechanisms checked on a case-by-case basis). NCBI
Gene–gene interactions across eye–kidney pathways (e.g., PAX–SIX–EYA–DACH network) considered when a single variant seems insufficient. NCBI
Fetal renal-specific genes that are still being discovered in unilateral renal agenesis cohorts (ongoing research). PubMed
Prenatal environmental factors that can cause renal agenesis alone (for example, maternal diabetes or certain drugs), which do not explain aniridia but can mimic part of the triad. Cleveland Clinic
Structural chromosomal rearrangements (balanced translocations) that disrupt regulatory landscapes—considered if microarray/exome are unrevealing. NCBI
Very rare single-family founder variants (the original report was in non-consanguineous parents, but single-family variants are possible in ultra-rare disorders). Genetic Diseases Info Center
Symptoms and signs
Note: Not everyone has every feature. The original 1974 family and modern summaries list the items below as part of the recognizable pattern. Genetic Diseases Info Center
Aniridia – the iris is partly absent, making the eyes look very dark and very sensitive to light. Vision can be reduced. Genetic Diseases Info Center
Congenital (developmental) glaucoma – high eye pressure beginning in infancy/childhood that can further damage vision. Genetic Diseases Info Center
Corneal clouding (opacity) – the clear front window of the eye becomes hazy over time in some children. Genetic Diseases Info Center
Strabismus – eyes that are not aligned (crossed or wandering). Genetic Diseases Info Center
Telecanthus – the inner eye corners are farther apart than usual, giving a wide-set appearance. Genetic Diseases Info Center
Frontal bossing – a prominent forehead. Genetic Diseases Info Center
Hypertelorism – the eyes are set wider apart. Genetic Diseases Info Center
Depressed nasal bridge or down-turned mouth corners – mild facial differences sometimes reported. Genetic Diseases Info Center
Unilateral renal agenesis – only one kidney formed. Many people with a single kidney do well, but blood pressure and urine protein need monitoring. Genetic Diseases Info Center
Hypotonia – low muscle tone, “floppy” feel in infancy. Genetic Diseases Info Center
Mild global developmental delay – later sitting, crawling, walking, and talking. Genetic Diseases Info Center
Short stature – height below the 3rd percentile in some children. Genetic Diseases Info Center
Micrognathia – small lower jaw. Genetic Diseases Info Center
Communicating hydrocephalus – extra fluid within the brain in some cases. Genetic Diseases Info Center
Ataxia or clumsy movement – poor balance/coordination reported in an expanded synonym (“aniridia-ataxia-renal agenesis-psychomotor delay”). Wikipedia
Diagnostic tests
In practice, clinicians tailor testing to the child. Because this condition is ultra-rare and the gene is unknown, doctors also test for look-alike conditions (especially PAX6/WAGR and CAKUT genes). NCBI+1
A) Physical examination
Eye inspection with a bright light – the clinician looks for a thin or missing iris (aniridia), large pupils, and light sensitivity. This is fast, painless, and guides all further eye testing. NCBI
Facial measurements – measuring inner-canthal distance confirms telecanthus and documents facial features such as frontal bossing or a low nasal bridge, which support the pattern described in the literature. Genetic Diseases Info Center
Growth and blood pressure check – height/weight/occipital-frontal head circumference help track development; blood pressure helps screen the single kidney’s function over time. (Children with a solitary kidney need routine BP and urine checks.) Genetic Diseases Info Center
Developmental/motor milestone exam – a pediatrician evaluates tone, reflexes, and age-appropriate skills to document psychomotor delay and plan early therapies. Genetic Diseases Info Center
B) Simple bedside “manual” tests
Cover–uncover test – detects strabismus (the eye that drifts will refixate when the other eye is covered). This is important because strabismus is common in aniridia. NCBI
Hirschberg corneal light reflex – a pen-light test that quickly checks eye alignment in infants. Abnormal reflexes point to strabismus requiring formal ophthalmology care. NCBI
Swinging-flashlight (pupil) test – checks the optic nerves and pupils; poor responses can reflect glaucoma or optic nerve involvement seen in aniridia disorders. NCBI
Tone and posture assessment – gentle passive movement and head/trunk control checks document hypotonia and guide physical therapy. Genetic Diseases Info Center
Gait/balance observation (when age-appropriate) – simple heel-to-toe or standing balance can reveal ataxia that matches caregiver reports of clumsiness. Wikipedia
C) Laboratory and pathological tests
Urinalysis and urine albumin-to-creatinine ratio – screens for protein or blood that might signal stress on the solitary kidney. Genetic Diseases Info Center
Serum creatinine/eGFR and electrolytes – monitors overall kidney function and trends over time. Genetic Diseases Info Center
Chromosomal microarray (CMA) – first-line test for small deletions/duplications (e.g., 11p13 PAX6/WT1 as in WAGR, which would change the diagnosis and surveillance). NCBI
Targeted gene panel or clinical exome sequencing – looks for variants in PAX6 (isolated aniridia), HNF1B, PAX2, GREB1L, and other CAKUT genes to rule in/out overlapping conditions while the specific gene for this syndrome remains unknown. NCBI+2MedlinePlus+2
Karyotype – detects large chromosomal rearrangements if microarray/exome are unrevealing and clinical suspicion remains. NCBI
D) Electrodiagnostic tests
Electroretinography (ERG) – measures retinal function; helpful if vision is worse than expected or to separate corneal/optic causes from retinal causes of low vision sometimes seen with aniridia. NCBI
Visual evoked potentials (VEP) – records brain responses to visual stimuli; useful in young children when standard vision testing is difficult. NCBI
E) Imaging tests
Renal / bladder ultrasound – the first-line imaging to confirm a single kidney, check its size and structure, and look for hydronephrosis or other urinary anomalies. Pediatrics Publications
Voiding cystourethrogram (VCUG) – an X-ray study, used selectively when ultrasound or infections suggest vesicoureteral reflux. Reflux is more common in children with a solitary kidney, so VCUG is often recommended in those with concerning findings. PubMed+1
Eye imaging (anterior segment OCT or ultrasound biomicroscopy) – shows how much iris tissue is present and maps corneal/angle changes that guide glaucoma management in aniridia-related disorders. NCBI
Brain MRI – ordered if there are signs of hydrocephalus, marked hypotonia, or suspected structural brain differences. This helps link neurologic signs to the overall syndrome picture. Genetic Diseases Info Center
Non-pharmacological Treatments (therapies & others)
(Each item: description, purpose, mechanism—kept concise so the full set fits here.)
Low-vision rehabilitation & optical aids – Early referral for magnifiers, high-contrast materials, tinted/photochromic lenses, and classroom accommodations improves functional vision and learning. Purpose: maximize usable vision. Mechanism: compensates for reduced acuity/photophobia by optimizing contrast, magnification, and glare control. NCBI
Photoprotection & glare control – Tinted lenses, hats, and room lighting adjustments reduce light sensitivity and eye strain. Purpose: comfort and safety. Mechanism: filters excessive light hitting a hypoplastic iris and macula. NCBI
Ocular surface hygiene & preservative-free lubrication – Scheduled preservative-free tears and lid care reduce dryness and epithelial stress, lowering the risk of keratopathy progression. Purpose: protect corneal surface. Mechanism: restores tear film and reduces inflammation from PAX6-related limbal niche dysfunction. PMC
Scleral or bandage contact lenses (specialist-fit) – Create a stable tear reservoir over the cornea to improve comfort and vision in keratopathy. Purpose: optical rehabilitation and epithelial protection. Mechanism: vaulting lens bathes epithelium and regularizes the optical surface. American Academy of Ophthalmology
Amblyopia prevention/therapy in childhood – Occlusion or penalization regimens and refractive correction prevent permanent suppression of a weaker eye. Purpose: maximize neurovisual development. Mechanism: drives cortical plasticity while the visual system is malleable. NCBI
Early Intervention: physical, occupational & speech therapy – Start as soon as delays are suspected to build motor, language, and self-care skills. Purpose: improve developmental trajectory. Mechanism: high-repetition, goal-oriented tasks leverage neuroplasticity in early childhood. AOTA Research+1
Orientation & mobility training – For significant low vision, teaches safe navigation and spatial skills. Purpose: independence and safety. Mechanism: structured skill acquisition using sensory cues and assistive techniques. NCBI
Individualized Education Plan (IEP) supports – Preferential seating, large-print materials, and extended testing time. Purpose: equitable learning access. Mechanism: accommodations counteract visual and processing barriers. GeneVision
Kidney-protective lifestyle (hydration, salt moderation, avoid nephrotoxins) – Maintain healthy BP and kidney workload in solitary kidney. Purpose: preserve long-term renal function. Mechanism: lowers intraglomerular pressure and nephron stress. PMC+1
Structured surveillance (BP/urine/eGFR) – Periodic checks detect early hypertension or proteinuria. Purpose: intervene early to prevent CKD. Mechanism: identifies hyperfiltration injury in solitary kidneys. PMC
Ultrasound-based Wilms tumor screening IF WT1 deletion present – Every 3 months to ~age 8 in WAGR-type deletions. Purpose: early tumor detection. Mechanism: image-based surveillance in genetically at-risk children. NCBI+1
Genetic counseling for family planning & prognosis – Explains testing (array CGH/MLPA), recurrence risk, and tailored surveillance. Purpose: informed decisions and targeted care. Mechanism: interprets genomic findings and connects phenotype to management. Nature
Nutritional counseling for solitary kidney/early CKD – Emphasize balanced protein, limit added salt, maintain healthy weight. Purpose: BP and kidney preservation. Mechanism: metabolic load reduction and BP control. PMC
Psychosocial & caregiver support – Address stress, access to services, and adherence barriers. Purpose: sustain therapy participation and quality of life. Mechanism: family-centered interventions improve outcomes for developmental conditions. Disability Research Institute
Vision-specific digital accessibility – Screen magnification, high-contrast themes, text-to-speech. Purpose: improve daily functioning. Mechanism: adaptive technology compensates for low vision. GeneVision
Infection prevention & prompt UTI care – Education on hydration and early evaluation of fever/dysuria in solitary kidney. Purpose: protect the single kidney. Mechanism: reduces pyelonephritis-related scarring risk. PMC
Regular ophthalmology follow-up – Monitor IOP, cornea, lens, and retina; aniridia demands lifelong reviews. Purpose: catch treatable complications early. Mechanism: surveillance and timely intervention. Orpha
Exercise & healthy sleep routines – Age-appropriate activity and sleep hygiene support neurodevelopment and BP control. Purpose: general health and kidney health. Mechanism: improves vascular tone, executive function, and mood. PMC
Transition planning to adult care – Prepare adolescents with solitary kidney/aniridia for adult nephrology and ophthalmology. Purpose: continuous care. Mechanism: structured hand-off reduces gaps in surveillance. PMC
Safety education (eye & kidney) – Protective eyewear for sports; avoid high-impact contact sports if advised by clinicians; medication safety. Purpose: injury prevention. Mechanism: reduces mechanical or drug-related kidney/eye harm. PMC
Drug Treatments
(Doses vary by age/weight; always use clinician-directed dosing. Pediatric cautions noted.)
Preservative-free lubricating eye drops (e.g., carboxymethylcellulose) – Class: ocular lubricants. When: daily to frequent. Purpose: relieve dryness/irritation in aniridia-associated keratopathy. Mechanism: stabilizes tear film and protects corneal epithelium; reduces microtrauma. Side effects: transient blur/irritation; preservative-free products minimize toxicity. PMC
Autologous serum tears (specialist use) – Class: biologic tear substitute. When: prescribed courses. Purpose: improve epithelial healing in moderate keratopathy. Mechanism: growth factors/vitamins mimic natural tears. Side effects: preparation logistics; infection risk minimized by sterile compounding. American Academy of Ophthalmology
Topical calcineurin inhibitor (cyclosporine 0.05%/0.1%) – Class: ocular immunomodulator. When: chronic for surface inflammation. Purpose: reduce inflammation that worsens keratopathy. Mechanism: T-cell modulation at the ocular surface. Side effects: burning/stinging. Evidence mainly extrapolated from ocular surface disease. PMC
Topical antibiotics (episodic) – Class: ophthalmic antibiotics. When: for suspected bacterial keratitis/abrasion per clinician. Purpose: prevent/treat infection in compromised cornea. Mechanism: pathogen eradication. Side effects: allergy, resistance risk with overuse—use only when indicated. American Academy of Ophthalmology
Intraocular pressure-lowering beta-blocker (timolol) – Class: topical β-blocker. When: glaucoma due to aniridia. Purpose: lower IOP to protect optic nerve. Mechanism: reduces aqueous humor production. Side effects: bradycardia/bronchospasm (systemic absorption)—pediatric caution and punctal occlusion techniques reduce risk. NCBI
Topical carbonic anhydrase inhibitor (dorzolamide) – Class: CAI. When: glaucoma. Purpose: adjunct or alternative to β-blocker. Mechanism: decreases aqueous production. Side effects: stinging, bitter taste; rare corneal edema. NCBI
Prostaglandin analog (latanoprost, etc.) – Class: uveoscleral outflow enhancers. When: glaucoma not controlled with first-line therapy. Purpose: lower IOP. Mechanism: increases uveoscleral outflow. Side effects: hyperemia, eyelash growth, iris pigmentation; pediatric use and aniridia eyes require specialist judgement. NCBI
Systemic carbonic anhydrase inhibitor (acetazolamide) – Class: oral CAI. When: short-term IOP control or peri-op use. Purpose: temporary IOP lowering. Mechanism: systemic aqueous suppression. Side effects: paresthesia, acidosis, kidney stone risk—dose/monitoring are essential. NCBI
ACE inhibitor (e.g., enalapril) – Class: antihypertensive/renoprotective. When: hypertension and/or proteinuria in solitary kidney or CKD. Purpose: reduce intraglomerular pressure and proteinuria. Mechanism: RAAS blockade. Side effects: cough, hyperkalemia; requires labs and clinician oversight. PMC
ARB (e.g., losartan) – Class: antihypertensive/renoprotective. When: ACEI intolerance or as alternative. Purpose/mechanism: RAAS blockade with similar renoprotection. Side effects: hyperkalemia, dizziness; avoid ACEI+ARB combination. PMC
Thiazide or loop diuretic – Class: diuretics. When: adjunct BP control/edema in CKD care. Purpose: optimize BP/volume status. Mechanism: natriuresis lowers BP load. Side effects: electrolyte changes—monitoring required. PMC
Vitamin D analog (e.g., cholecalciferol or active forms if CKD-MBD) – Class: vitamin/hormone. When: deficiency or CKD-related bone/mineral disorder. Purpose: bone health, PTH control. Mechanism: corrects vitamin D axis. Side effects: hypercalcemia if misused—lab guidance needed. PMC
Erythropoiesis-stimulating agent (CKD anemia) – Class: ESA. When: clinician-diagnosed CKD anemia. Purpose: improve hemoglobin/symptoms. Mechanism: stimulates RBC production. Side effects: hypertension, thrombosis risk—specialist dosing only. PMC
Oral iron (if iron-deficient) – Class: iron supplement. When: iron deficiency with or without CKD anemia. Purpose: replete iron stores. Mechanism: substrate for erythropoiesis. Side effects: GI upset; monitor ferritin/TSAT. PMC
Antibiotic prophylaxis (selected infants with high-grade VUR) – Class: low-dose antibiotic. When: specialist-defined vesicoureteral reflux risk. Purpose: reduce recurrent UTIs that could scar the single kidney. Mechanism: lowers bacterial ascent. Side effects: resistance, allergy—use only when risk justifies. PMC
Topical anti-inflammatories (short steroid courses under supervision) – Class: ophthalmic corticosteroids. When: acute corneal surface inflammation. Purpose: decrease inflammation to protect epithelium. Mechanism: cytokine suppression. Side effects: steroid-induced IOP rise, cataract—ophthalmologist supervision critical. American Academy of Ophthalmology
Hypertonic saline for corneal edema (selected cases) – Class: topical osmotic agent. When: epithelial edema affects vision/comfort. Purpose: reduce edema and improve clarity. Mechanism: draws fluid from cornea. Side effects: stinging. American Academy of Ophthalmology
Antihistamine/mast-cell stabilizer drops (if co-existing allergy) – Class: anti-allergy drops. When: allergic conjunctivitis worsens surface disease. Purpose: itch relief, reduce eye rubbing (which harms cornea). Mechanism: blocks histamine and mast-cell mediator release. Side effects: mild stinging. American Academy of Ophthalmology
Analgesics/antipyretics (kidney-safe choices) – Class: e.g., acetaminophen preferred for fever/pain. Purpose: symptom control while avoiding NSAID nephrotoxicity in a solitary kidney. Mechanism: central COX inhibition with minimal renal impact at correct dosing. Side effects: liver toxicity if overdosed—follow clinician guidance. PMC
Glaucoma combination drops (specialist-directed) – Class: e.g., timolol/dorzolamide combo to reduce drop burden. Purpose: adherence and IOP control. Mechanism: dual aqueous suppression. Side effects: mix of components; pediatric safety review needed. NCBI
Important pediatric caution: α2-agonist brimonidine can cause CNS depression in young children and is generally avoided—specialist decision only. NCBI
Dietary Molecular Supplements
Omega-3 fatty acids – May support ocular surface comfort in dry-eye–like symptoms; evidence mixed. Dose: per clinician. Function/Mechanism: anti-inflammatory lipid mediators may stabilize tear film. American Academy of Ophthalmology
Vitamin D (deficiency correction) – For those deficient or with CKD-related bone issues. Function: calcium-phosphate balance, bone health. Mechanism: endocrine modulation of mineral metabolism. PMC
Lutein/zeaxanthin (vision nutrition) – May aid retinal/visual performance; not ARAP-specific. Mechanism: macular pigment antioxidant effects. Use: adjunct only. GeneVision
Oral rehydration emphasis (not a pill, but a regimen) – Adequate fluids to support solitary kidney perfusion unless restricted by clinicians. Mechanism: maintains euvolemia and renal perfusion. PMC
Probiotics (UTI risk contexts—evolving evidence) – Certain strains investigated for UTI reduction; consult nephrology/urology. Mechanism: microbiome modulation. PMC
Iron (if iron-deficient) – Supports hemoglobin and cognition. Mechanism: substrate for erythropoiesis and neural myelination. Dose: labs-guided. PMC
Folate/B-complex (nutritional gaps) – General neural support when diets are limited; not disease-specific. Mechanism: cofactor roles in neurodevelopment/hematopoiesis. Disability Research Institute
Electrolyte-balanced hydration strategies – For active children/adolescents with solitary kidney; avoid energy drinks with high caffeine/salt. Mechanism: maintain BP/renal perfusion. PMC
Protein moderation (dietary plan, not a supplement) – Balanced intake tailored to growth and kidney status. Mechanism: minimizes hyperfiltration load. PMC
Avoid unregulated “kidney detox/eye cure” products – Many are nephrotoxic or ineffective. Mechanism: harm avoidance. PMC
Immunity-booster / regenerative / stem-cell” drugs
There are no approved systemic “stem-cell drugs” for ARAP. However, cell-based ocular procedures like limbal stem cell transplantation (e.g., KLAL/CLET/SLET) may be considered by corneal specialists for severe aniridia-associated keratopathy. These are procedures, not daily medicines; success depends on ocular surface status and lifelong care. Experimental gene-based therapies for PAX6-related disease are under study; none are standard of care yet. For kidney disease, no immune-boosting or stem-cell drug has proven benefit; renal protection relies on BP/proteinuria control and surveillance. American Academy of Ophthalmology+1
(Six items summarized in one safer evidence-based paragraph to avoid implying specific “doses” for unapproved therapies.)
Surgeries
Cataract extraction (with IOL when appropriate) – Treats visually significant cataract common in aniridia to improve clarity; surgical planning accounts for weak zonules and glaucoma risk. NCBI
Glaucoma surgery (trabeculectomy/tube shunt) – For IOP uncontrolled by drops; protects optic nerve from damage related to aniridia-associated glaucoma. NCBI
Amniotic membrane transplantation – For ocular surface healing in moderate disease, sometimes combined with other surface reconstruction. American Academy of Ophthalmology
Limbal stem cell transplantation (CLET/SLET/KLAL) – Replaces/augments limbal stem cells in severe aniridia-associated keratopathy to restore a stable epithelium. PMC
Renal replacement procedures (dialysis/transplant) – For end-stage kidney disease from any cause; not ARAP-specific but relevant to solitary kidney patients with progressive CKD. PMC
Preventions
Know your genes: If aniridia is present, ask about WT1 testing; tumor screening depends on it. NCBI
Regular eye checks to catch glaucoma/corneal problems early. Orpha
Protect the cornea with preservative-free tears and avoid eye rubbing. PMC
Sun and glare protection daily. NCBI
Kidney surveillance (BP, urine albumin, labs) per schedule. PMC
Avoid NSAIDs unless prescribed; choose kidney-safer options. PMC
Hydrate and limit added salt to help BP. PMC
Treat UTIs promptly to protect the single kidney. PMC
Early therapy for any delay—don’t wait. AOTA Research
Keep vaccinations up to date to prevent infections impacting overall health. Disability Research Institute
When to see doctors (red flags)
Seek urgent care for eye pain, sudden vision drop, halos, or redness (possible glaucoma/keratitis); fever with flank pain or painful urination (possible UTI); new abdominal mass or blood in urine (tumor/UTI); headaches or elevated home BPs; or developmental regression. Routine visits: ophthalmology (per plan), nephrology (BP/urine/labs), pediatrics/therapy teams for growth and developmental milestones. If WT1 deletion is confirmed, follow Wilms tumor ultrasound schedule every 3 months to about age 8. NCBI+2PMC+2
What to eat and what to avoid
Eat: balanced meals with fruits/vegetables, whole grains, calcium-rich foods, and moderate protein appropriate for age; drink enough fluids unless restricted; choose low-sodium options; use healthy fats. Avoid/limit: excess salt, heavily processed snacks, high-sugar drinks, NSAIDs without guidance, energy drinks with high caffeine/sodium, and unregulated “detox/eye cure” supplements. Personalize plans with a renal dietitian if kidney labs change. PMC
Frequently Asked Questions
Is ARAP the same as WAGR?
No. ARAP is a two-sibling case series from 1974 with aniridia, unilateral renal agenesis, and mild psychomotor delay. WAGR is a confirmed 11p13 deletion syndrome (WT1/PAX6) with defined surveillance (e.g., Wilms tumor). Genetic testing helps tell them apart. Genetic Diseases Info Center+1How rare is ARAP?
Extremely—only that original family is well-documented. Most current guidance therefore uses evidence from aniridia, solitary kidney care, and developmental therapy literature. Genetic Diseases Info CenterWhat testing should be done if my child has aniridia and a kidney anomaly?
Ask for PAX6/WT1-region testing (e.g., array CGH/MLPA) and see genetics. Results change surveillance plans. NatureDoes aniridia always mean WT1 deletion?
No. Many aniridia cases are isolated PAX6 variants without WT1 deletion; tumor screening is then different. NCBIWhat is the Wilms tumor screening schedule in WT1 deletion syndromes?
Typically abdominal ultrasound every 3 months until about age 8 (details vary by center). NCBI+1Can the eye surface be rebuilt?
Sometimes. Amniotic membrane and limbal stem cell transplantation (CLET/SLET/KLAL) are options in severe keratopathy—specialist assessment needed. American Academy of Ophthalmology+1Which glaucoma drops are used in aniridia?
Common classes include β-blockers, CAIs, and prostaglandin analogs. Pediatric safety and anatomy in aniridia require specialist tailoring. NCBIShould we avoid certain pain medicines with a solitary kidney?
Often yes—NSAIDs can stress kidneys. Use clinician-approved alternatives (e.g., acetaminophen within safe limits). PMCDoes Early Intervention really help?
Yes—robust evidence shows early, family-centered OT/PT/speech improves development and reduces later support needs. AOTA Research+1Will one kidney last a lifetime?
Many people with a congenital solitary kidney do well, but BP and urine protein must be monitored to catch hyperfiltration injury early. PMCAre there gene therapies for aniridia now?
Research is active, but no approved PAX6 gene therapy yet; management focuses on protecting the ocular surface and controlling IOP. PMCIs there a special diet?
No single ARAP diet. Use kidney-healthy principles (adequate fluids, limit added salt, balanced protein) individualized by clinicians. PMCDo children outgrow screening needs?
WT1-related Wilms screening usually stops around age 8, but lifelong kidney function and eye follow-up continue. NCBIHow often should eye pressure be checked?
As advised by ophthalmology; aniridia needs lifelong follow-up due to glaucoma/corneal risks. OrphaWhere can families learn more?
Authoritative overviews: GARD, Orphanet, GeneReviews, NORD, and WAGR syndrome foundation resources for surveillance in WT1 deletions. NORD+3Genetic Diseases Info Center+3Orpha+3
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 17, 2025.
